全文获取类型
收费全文 | 35755篇 |
免费 | 2258篇 |
国内免费 | 1230篇 |
专业分类
耳鼻咽喉 | 64篇 |
儿科学 | 914篇 |
妇产科学 | 667篇 |
基础医学 | 1896篇 |
口腔科学 | 60篇 |
临床医学 | 4213篇 |
内科学 | 10914篇 |
皮肤病学 | 43篇 |
神经病学 | 854篇 |
特种医学 | 880篇 |
外科学 | 2641篇 |
综合类 | 7095篇 |
现状与发展 | 5篇 |
预防医学 | 1854篇 |
眼科学 | 696篇 |
药学 | 4745篇 |
27篇 | |
中国医学 | 1519篇 |
肿瘤学 | 156篇 |
出版年
2024年 | 40篇 |
2023年 | 456篇 |
2022年 | 593篇 |
2021年 | 1215篇 |
2020年 | 1235篇 |
2019年 | 1053篇 |
2018年 | 1140篇 |
2017年 | 1077篇 |
2016年 | 1162篇 |
2015年 | 1164篇 |
2014年 | 2366篇 |
2013年 | 3247篇 |
2012年 | 1911篇 |
2011年 | 1983篇 |
2010年 | 1732篇 |
2009年 | 1602篇 |
2008年 | 1550篇 |
2007年 | 1715篇 |
2006年 | 1541篇 |
2005年 | 1310篇 |
2004年 | 1210篇 |
2003年 | 1112篇 |
2002年 | 924篇 |
2001年 | 910篇 |
2000年 | 769篇 |
1999年 | 650篇 |
1998年 | 558篇 |
1997年 | 601篇 |
1996年 | 499篇 |
1995年 | 525篇 |
1994年 | 437篇 |
1993年 | 305篇 |
1992年 | 321篇 |
1991年 | 263篇 |
1990年 | 231篇 |
1989年 | 196篇 |
1988年 | 208篇 |
1987年 | 176篇 |
1986年 | 161篇 |
1985年 | 206篇 |
1984年 | 189篇 |
1983年 | 88篇 |
1982年 | 118篇 |
1981年 | 118篇 |
1980年 | 124篇 |
1979年 | 61篇 |
1978年 | 44篇 |
1977年 | 47篇 |
1976年 | 40篇 |
1973年 | 16篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
21.
Tian-Yuan Xiong Fang-Yang Huang Qi Liu Yong Peng Yuan-Ning Xu Jia-Fu Wei 《Annals of medicine》2020,52(7):361-366
Abstract
Background
Comorbidities are commonly seen in patients with coronavirus disease 2019 (COVID-19), but the clinical implication is not yet well-delineated. We aim to characterize the prevalence and clinical implications of comorbidities in patients with COVID-19. 相似文献22.
23.
24.
Wilbert S Aronow 《Expert opinion on pharmacotherapy》2016,17(2):205-215
Introduction: It is important to know how to treat hypertension in patients with coronary artery disease (CAD). The reason for the review was to update this treatment and to discuss the 2015 American Heart Association/American College of Cardiology/American Society of Hypertension 2015 guidelines of treatment of hypertension in patients with CAD.Areas covered: Studies between 1968 and 2015 were reviewed on treatment of hypertension in patients with CAD using a Medline search, and studies between 1977 and 2015 were reported. Hypertension should be treated with beta blockers and ACE inhibitors or angiotensin receptor blockers (ARBs). Long-acting nitrates are effective antianginal and anti-ischemic drugs. Calcium-channel blockers (CCBs) may be added if angina persists despite beta blockers and long-acting nitrates. The 2015 guidelines recommend that the blood pressure should be < 140/90 mm Hg in patients aged ≤ 80 years and the systolic blood pressure < 150 mm Hg if they are ≥ 80 years.Expert opinion: Hypertension in patients with CAD should be treated with beta blockers and ACE inhibitors or ARBs. Long-acting nitrates are effective antianginal and anti-ischemic drugs. CCBs may be added if angina persists despite beta blockers and long-acting nitrates. The blood pressure should be < 140/90 mm Hg in patients aged < 80 years and the systolic blood pressure < 150 mm Hg if they are ≥ 80 years. 相似文献
25.
Lesley A. Inker Morgan E. Grams Andrew S. Levey Josef Coresh Massimo Cirillo John F. Collins Ron T. Gansevoort Orlando M. Gutierrez Takayuki Hamano Gunnar H. Heine Shizukiyo Ishikawa Sun Ha Jee Florian Kronenberg Martin J. Landray Katsuyuki Miura Girish N. Nadkarni Carmen A. Peralta Dietrich Rothenbacher Mark Woodward 《American journal of kidney diseases》2019,73(2):206-217
26.
目的 采用网络药理学阐明济脉通片多成分-多靶点-多途径的作用理念,为进一步研究济脉通片降压药效物质基础和机制提供一定理论参考。方法 通过TCMSP数据库,结合口服利用度(≥ 30%)和类药性分析(≥ 0.18)参数,筛选济脉通片的活性成分;通过Drugbank和TCMSP数据库进行靶点预测分析;通过GENCARD数据库筛选出高血压疾病相关基因;结合DAVID和KEGG数据库进行GO分析和通路分析;使用Cystoscope软件构建"化合物-靶点-作用通路"网络图。结果 经筛选后得到济脉通片的33个化合物,148个潜在靶基因并映射到了223条信号通路,其中31条信号通路与高血压的发生发展密切相关,其中AGE-RAGE signaling pathway in diabetic complications、PI3K-Akt signaling pathway、TNFsignaling pathway、Adrenergic signaling in cardiomyocytes和Focal adhesion为重要的通路枢纽。结论 济脉通片主要通过多成分、多靶点、多通路调节血管内皮功能、炎症反应、钙钠离子转运、糖脂代谢等参与血管舒张、改善炎症、调节机体代谢、调节离子转运等而产生降压作用。 相似文献
27.
Jennifer Wang Jonathan G. Stine Scott L. Cornella Curtis K. Argo Steven M. Cohn 《临床与转化肝病杂志(英文版)》2015,3(4):254-259
Background and Aims: Gastric antral vascular ectasia (GAVE) is commonly found in patients with cirrhosis, but it is also associated with other diseases in the absence of cirrhosis. Whether GAVE confers a different severity of gastrointestinal (GI) bleeding between patients with and without cirrhosis remains unknown. We aim to examine whether there is a difference in clinically significant GI bleeding due to GAVE in patients with or without cirrhosis. Methods: This is a retrospective case-control study of patients who were diagnosed with GAVE between January 2000 and June 2014. Patients were categorized into cirrhosis and noncirrhosis groups, and those with an additional GI bleeding source were excluded. Univariate comparisons and multivariable models were constructed using logistic regression. Results: In total, 110 patients diagnosed with GAVE on esophagogastroduodenoscopy (EGD) were included in our analysis; 84 patients had cirrhosis (76.4%) and 26 (23.6%) did not. Active GI bleeding was more prevalent in patients without cirrhosis (63.4% vs. 32.1%, p=0.003) despite similar indications for EGD, and endoscopic treatment with argon plasma coagulation (APC) was required more often in this group, approaching statistical significance (27% vs. 10.7%, p=0.056). There was no difference in bleeding severity, as evidenced by similar re-bleeding rates, surgery, or death attributed to uncontrolled bleeding. The strongest independent risk factor for GI bleeding was the absence of cirrhosis (odds ratio (OR): 5.151 (95% confidence interval (CI): 1.08-24.48, p=0.039). Conclusions: Patients with GAVE in the absence of cirrhosis are at higher risk for active GI bleeding and require more frequent endoscopic treatment than similar patients with cirrhosis. It may be worthwhile to treat GAVE in this population even in the absence of active bleeding. 相似文献
28.
AbstractBackground: This study aims to compare the effectiveness of inhaled prostacyclin or its analoguesversus nitric oxide (NO) in treating pulmonary hypertension (PH) after cardiac or pulmonary surgery remains unclear.Methods: PubMed, Cochrane, and Embase databases were searched for literature published prior to December 2019 using the following keywords: inhaled, nitric oxide, prostacyclin, iloprost, treprostinil, epoprostenol, Tyvaso, flolan, and pulmonary hypertension. Randomized controlled trials and multiple-armed prospective studies that evaluated inhaled NO versus prostacyclin (or analogues) in patients for perioperative and/or postoperative PH after either cardiac or pulmonary surgery were included. Retrospective studies, reviews, letters, comments, editorials, and case reports were excluded.Results: Seven studies with a total of 195 patients were included. No difference in the improvement of mean pulmonary arterial pressure (pooled difference in mean change= ?0.10, 95% CI: ?3.98 to 3.78, p?=?.959) or pulmonary vascular resistance (pooled standardized difference in mean change= ?0.27, 95% CI: ?0.60 to 0.05, p?=?.099) were found between the two treatments. Similarly, no difference was found in other outcomes between the two treatments or subgroup analysis.Conclusions: Inhaled prostacyclin (or analogues) was comparable to inhaled NO in treating PH after cardiac or pulmonary surgery.
- Key messages
This study compared the efficacy of inhaled prostacyclin or its analogues versus inhaled NO to treat PH after surgery. The two types of agent exhibited similar efficacy in managing MPAP, PVR, heart rate, and cardiac output was observed.
Inhaled prostacyclin may serve as an alternative treatment option for PH after cardiac or pulmonary surgery.
29.
Characterization of Left Atrial Mechanics in Hypertrophic Cardiomyopathy and Essential Hypertension Using Vector Velocity Imaging 下载免费PDF全文
30.